Home > News > NCI Seminar Highlights Progress in Anticancer Nanomedicines
October 5th, 2005
NCI Seminar Highlights Progress in Anticancer Nanomedicines
Abstract:
Though many observers believe that the application of nanotechnology in medicine is a recent phenomenon, "progress in the development of nano-sized hybrid therapeutics and nanosized drug delivery systems over the past decade has been remarkable," said Ruth Duncan, Ph.D., director of the center for polymer therapeutics at Cardiff University in Wales. Speaking at the most recent NCI-sponsored Nanotechnology Seminar Series, Duncan noted that routine clinical use and clinical development of nano-sized drug delivery vectors including liposomes, antibody conjugates, nanoparticles and polymer therapeutics as anticancer treatments is growing rapidly.
Source:
nano.cancer.gov
Related News Press |
Possible Futures
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
With VECSELs towards the quantum internet Fraunhofer: IAF achieves record output power with VECSEL for quantum frequency converters April 5th, 2024
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||